+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.

Age: 18Years +All GendersPhase 3
279 locations
S

Actively Recruiting

Researchers are evaluating pembrolizumab combined with carboplatin and taxane chemotherapy followed by pembrolizumab with or without maintenance sacituzumab tirumotecan sac-TMT as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC. This phase 3 study aims to determine if adding maintenance sac-TMT improves overall survival compared to pembrolizumab alone. Participants first undergo an induction phase consisting of four cycles of pembrolizumab every three weeks, carboplatin every three weeks, and either paclitaxel every three weeks or nab-paclitaxel weekly. After induction, participants are randomly assigned to receive either pembrolizumab maintenance alone or pembrolizumab combined with sac-TMT maintenance. The maintenance phase involves pembrolizumab every six weeks for up to 96 weeks and sac-TMT infusions every two weeks until discontinuation criteria are met. Throughout the study, participants will have tumor assessments, scans, and evaluations to monitor disease status, side effects, and quality of life. Researchers will measure overall survival up to approximately 50 months and progression-free survival up to 79 months, along with patient-reported symptoms such as dyspnea, cough, and chest pain. Safety monitoring includes tracking adverse events and treatment discontinuations. The total participation may last several years as long-term outcomes are assessed.

Age: 18Years +All GendersPhase 3
217 locations
C

Actively Recruiting

Pelvic organ prolapse POP, especially defects in the anterior compartment, significantly affects the quality of life in women. This trial focuses on comparing two surgical methods to repair cystocele, a common type of POP caused mainly by paravaginal defects in vaginal support. The study aims to evaluate the safety and effectiveness of a new minimally invasive surgery called transobturator cystocele repair TOCR against the standard anterior colporrhaphy AR to improve cystocele repair outcomes over one year. Participants will receive either the novel TOCR procedure or the standard AR surgery. TOCR involves a transvaginal approach using continuous non-locking stitches through the obturator membrane and muscle with non-absorbable sutures, followed by closure of the vaginal skin. The AR technique uses a midline vaginal incision to dissect and repair the pubocervical fascia with interrupted sutures and trims excess vaginal tissue. Both groups receive indometacin rectal suppositories for early postoperative pain management. Women in the trial will undergo assessments before and after surgery, including anatomical evaluations of prolapse repair success at 1 and 2 years, complication monitoring, pain assessment 14 days post-surgery, and questionnaires on subjective improvement and quality of life related to urinary and pelvic symptoms. The study includes follow-up visits to measure patient satisfaction and monitor new urinary symptoms. The total follow-up period extends up to two years to observe long-term outcomes and safety.

Age: 50Years +FEMALEPhase Not Applicable
8 locations